All CIRM Grants

Institution Researcher name Grant Type Grant Title Award Value
University of California, Davis Roslyn Isseroff Early Translational II Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds $4,629,747
University of California, Los Angeles Sophie Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $697,507
University of California, San Francisco Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $2,756,536
University of California, San Francisco Arturo Alvarez-Buylla Early Translational II Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy $1,564,016
University of California, Los Angeles Bruno Peault Early Translational II Harnessing native fat-residing stem cells for bone regeneration $5,359,076
University of California, Irvine Brian Cummings Early Translational II Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767
Cedars-Sinai Medical Center Dan Gazit Early Translational II Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures $1,927,698
City of Hope, Beckman Research Institute Yanhong Shi Early Translational II Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
Children's Hospital of Los Angeles Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $850,769
Stanford University Michele Calos Early Translational II Stem Cell Therapy for Duchenne Muscular Dystrophy $2,267,261
Buck Institute for Age Research Xianmin Zeng Early Translational II Banking transplant ready dopaminergic neurons using a scalable process $4,983,013
University of California, Irvine leif Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $1,527,011
University of California, Davis Mark Zern Early Translational II Liver Cell Transplantation $4,212,621
University of California, Santa Barbara Peter Coffey Research Leadership Development of Cellular Therapies for Retinal Disease $4,690,963
Salk Institute for Biological Studies Fred Gage Early Translational II Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model $2,472,839
University of California, Los Angeles Noriyuki Kasahara Early Translational II Stem cell-based carriers for RCR vector delivery to glioblastoma $3,340,625
University of California, San Diego Catriona Jamieson Early Translational II Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy $3,103,041
Vitalant Research Institute Elizabeth Read Conference Translation of Stem Cell Therapies: Strategies and Best Practices for PreClinical Developments $25,000
University of California, San Francisco Emmanuelle Passegue Conference CA-HSCI 1st Generation Stem Cell PI Meeting $20,000
International Society for Stem Cell Research Irving Weissman Conference ISSCR 8th Annual Meeting - San Francisco $62,475
Sanford Burnham Prebys Medical Discovery Institute Robert Wechsler-Reya Research Leadership The role of neural stem cells in cerebellar development, regeneration and tumorigenesis $5,226,049
University of California, Irvine Aileen Anderson Basic Biology II Role of the microenvironment in human iPS and NSC fate and tumorigenesis $1,256,194
University of California, San Francisco Jeffrey Bluestone Transplantation Immunology Stem cell tolerance through the use of engineered antigen-specific regulatory T cells $1,152,768
Stanford University Kenneth Weinberg Transplantation Immunology Engineered immune tolerance by Stem Cell-derived thymic regeneration $1,271,729
University of California, Irvine Marian Waterman Basic Biology II TCF-3: A Wnt Pathway Effector and Nanog Regulator in Pluripotent Stem Cell Self-Renewal $1,259,879
Stanford University Christopher Contag Transplantation Immunology Engineering Embryonic Stem Cell Allografts for Operational Tolerance $1,411,338
University of California, San Diego Yang Xu Transplantation Immunology Induction of immune tolerance to human embryonic stem cell-derived allografts $1,192,680
University of California, San Diego Dong-Er Zhang Basic Biology II RUNX1 in maintenance, expansion, and differentiation of therapeutic pluripotent stem cells $1,371,540
University of California, Los Angeles Gay Crooks Transplantation Immunology Engineering Thymic Regeneration to Induce Tolerance $1,235,445
University of California, San Diego Kun-Liang Guan Basic Biology II The function of YAP in human embryonic stem cells $1,245,693
Scripps Research Institute Nicholas Gascoigne Transplantation Immunology Role of Innate Immunity in hematopoeitic stem cell-mediated allograft tolerance $1,705,554
University of California, Los Angeles Benhur Lee Basic Biology II The EphrinB2/EphB4 axis in regulating hESC pluripotency and differentiation $1,371,936
Palo Alto Veterans Institute for Research Husein Hadeiba Transplantation Immunology Application of Tolerogenic Dendritic Cells for Hematopoietic Stem Cell Transplantation $733,061
Stanford University Aaron Hsueh Basic Biology II Maturation of Human Oocytes for SCNT and Embryonic Stem Cell Derivation $1,309,018
Escape Therapeutics, Inc Basil Hantash Transplantation Immunology Development of an immune tolerant hESC source for allogeneic cell therapy applications $1,453,040
Salk Institute for Biological Studies Ronald Evans Basic Biology II Molecular Characterization and Functional Exploration of Nuclear Receptors in hiPSCs $1,712,880
Scripps Research Institute Jeanne Loring Transplantation Immunology Thymus based tolerance to stem cell therapies $1,108,921
iPierian, Inc. Irene Griswold-Prenner Basic Biology II Cellular Reprogramming: Dissecting the Molecular Mechanism and Enhancing Efficiency $1,458,000
Cedars-Sinai Medical Center Terrence Town Transplantation Immunology Role of HLA in neural stem cell rejection using humanized mice $1,119,385
University of California, San Francisco Tippi MacKenzie Transplantation Immunology Maternal and Fetal Immune Responses to In Utero Hematopoietic Stem Cell Transplantation $1,230,869
University of California, Davis Eric Kurzrock Basic Biology II Differentiation of Human Embryonic Stem Cells into Urothelium $849,037
University of California, San Diego Martin Marsala Transplantation Immunology Induction of immune tolerance after spinal grafting of human ES-derived neural precursors $1,387,800
Palo Alto Veterans Institute for Research Tony Wyss-Coray Basic Biology II Systemic Protein Factors as Modulators of the Aging Neurogenic Niche $1,159,806
University of California, Davis William Murphy Transplantation Immunology Donor natural killer (NK) cells as “veto” cells to promote donor-specific tolerance $1,257,601
University of California, Los Angeles Douglas Black Basic Biology II Programs of alternative splicing regulation by polypyrimidine tract binding protein $1,344,562
Stanford University Robert Negrin Transplantation Immunology Regulatory T cell induced tolerance to ESC transplantation $1,382,658
University of California, Los Angeles Yong Kim Basic Biology II Novel Mechanism in Self-Renewal/Differentiation of Human Embryonic Stem Cells $1,259,371
La Jolla Institute for Allergy and Immunology Anjana Rao Transplantation Immunology Generation of regulatory T cells by reprogramming $1,464,446
Stanford University Steven Artandi Basic Biology II Self-renewal and senescence in iPS cells derived from patients with a stem cell disease $931,285
University of California, Berkeley David Raulet Transplantation Immunology Inactivating NK cell reactivity to facilitate transplantation of stem cell derived tissue $952,896
Sanford Burnham Prebys Medical Discovery Institute Huei-sheng Chen Basic Biology II Endothelial cells and ion channel maturation of human stem cell-derived cardiomyocytes $1,587,610
University of California, Berkeley Ellen Robey Transplantation Immunology Human Immune System Mouse models as preclinical platforms for stem cell derived grafts $1,005,605
University of California, San Francisco John Rubenstein Basic Biology II MGE Enhancers to Select for Interneuron Precursors Produced from Human ES Cells $1,387,800
Stanford University Judith Shizuru Transplantation Immunology Purified allogeneic hematopoietic stem cells as a platform for tolerance induction $1,233,275
Stanford University Garry Nolan Basic Biology II Kinase signaling analysis of iPS cell reprogramming and differentiation $1,343,100
University of California, San Francisco Mark Anderson Transplantation Immunology Stem cell differentiation to thymic epithelium for inducing tolerance to stem cells $1,314,089
University of Southern California Terrence Town Transplantation Immunology Role of HLA in neural stem cell rejection using humanized mice $353,249
University of California, Irvine Peter Donovan Conference Systems Biology of Stem Cells $25,000
City of Hope, Beckman Research Institute Karen Aboody Disease Team Research I Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $17,890,623
Stanford University Gary Steinberg Disease Team Research I Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $17,244,851
University of California, Los Angeles Dennis Slamon Disease Team Research I Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors $19,979,660
University of California, Los Angeles Donald Kohn Disease Team Research I Stem Cell Gene Therapy for Sickle Cell Disease $8,833,695
Stanford University Irving Weissman Disease Team Research I Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276
ViaCyte, Inc. Allan Robins Disease Team Research I Cell Therapy for Diabetes $22,999,933
Calimmune, Inc. Geoff Symonds Disease Team Research I GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE $8,278,722
Cedars-Sinai Medical Center Eduardo Marbán Disease Team Research I Autologous cardiac-derived cells for advanced ischemic cardiomyopathy $5,560,232
City of Hope, Beckman Research Institute John Zaia Disease Team Research I ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS $14,536,969
University of California, Los Angeles Irvin Chen Disease Team Research I HPSC based therapy for HIV disease using RNAi to CCR5. $9,905,604
University of California, San Francisco Mitchel Berger Disease Team Research I Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) $6,214,914
University of Southern California Mark Humayun Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
University of California, Los Angeles Irvin Chen Early Translational from Disease Team Conversion Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. $1,505,000
University of California, San Diego Lawrence Goldstein Disease Team Research I Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $5,694,308
University of California, San Diego Lawrence Goldstein Early Translational from Disease Team Conversion Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $4,139,754
University of California, San Diego Dennis Carson Disease Team Research I Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826
Stanford University Alfred Lane Disease Team Research I iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa $11,039,208
Sanford Consortium for Regenerative Medicine Edward Holmes Conference Stem Cell Meeting on the Mesa $40,000
University of Southern California Wange Lu Basic Biology I Defining the molecular mechanisms of somatic cell reprogramming $1,365,580
University of California, Los Angeles Luisa Iruela-Arispe Basic Biology I Molecular Characterization and Functional Exploration of Hemogenic Endothelium $1,371,477
University of California, Los Angeles Bennett Novitch Basic Biology I Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons $1,229,922
University of Southern California Martin Pera Basic Biology I The stem cell microenvironment in the maintenance of pluripotency and reprogramming $1,325,723
University of California, Los Angeles Michael Teitell Basic Biology I Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer $1,323,029
Stanford University Susan McConnell Basic Biology I Identification and characterization of human ES-derived DA neuronal subtypes $1,404,853
University of California, San Diego Eugene Yeo Basic Biology I RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency $1,308,901
Stanford University Julien Sage Basic Biology I The retinoblastoma (RB) gene family in cellular reprogramming $1,357,085
Stanford University Helen Blau Basic Biology I Molecular Mechanisms of Reprogramming towards Pluripotency $1,408,332
University of California, San Diego Karl Willert Basic Biology I WNT signaling and the control of cell fate decisions in human pluripotent stem cells. $1,329,298
University of California, Los Angeles Robb Maclellan Basic Biology I Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate $917,667
University of California, Davis Min Zhao Basic Biology I Directing migration of human stem cells with electric fields $816,228
City of Hope, Beckman Research Institute Richard Jove Conference Innovation and Translational Stem Cell Therapy for Diabetes and Neurological Diseases: Paving the way for real life solutions $14,878
University of California, San Francisco Arnold Kriegstein Conference UCSF Frontiers of Neural Stem Cells Symposium $35,000
Stanford University Hank Greely Conference Stem Cell Policy: Understanding the Scientific and Legal Challenges Ahead $5,838
University of California, Los Angeles Gabriel Travis Early Translational I Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration $5,487,136
Salk Institute for Biological Studies Inder Verma Early Translational I Curing Hematological Diseases $5,979,252
Sanford Burnham Prebys Medical Discovery Institute Evan Snyder Early Translational I Developmental Candidates for Cell-Based Therapies for Parkinson's Disease (PD) $5,190,752
University of California, Davis Alice Tarantal Early Translational I In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies $3,143,392
BioTime, Inc. Michael West Early Translational I Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines $4,721,706
University of California, Davis Jan Nolta Early Translational I Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders $2,615,674
University of California, Irvine Frank LaFerla Early Translational I Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease $3,599,997
University of California, San Diego Yang Xu Early Translational I Developing induced pluripotent stem cells into human therapeutics and disease models $5,165,028
Scripps Research Institute Jeanne Loring Early Translational I Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation $5,830,771

Pages

Icon for xls export